



EITA INDIA LIMITED
[FORMERLY: E.I.T.A India Limited]
CIN: L51109WB1983PLC035969
Regd. Office: 20-B, Abdul Hamid Street,
4th Floor, Kolkata-700 069,
Phone: 033-22483203
E-mail: eita.cal@eitain.com,
Website: www.eitain.com

NOTICE
Notice is hereby given that pursuant to
Regulation 29 read with Regulation 47 of
SEBI (Listing Obligations & Disclosure
Requirements) Regulations, 2015 meeting
of the Board of Directors of the Company will
be held at its Registered office at 20B Abdul
Hamid Street, 4th Floor, Kolkata- 700069 on
Tuesday 12th August, 2025 at 1.00 P.M.,
inter alia to consider and take on record the
Unaudited Financial Results of the Company
for the quarter ended June 30, 2025.

**By Order of the Board
For EITA India Limited**
Sd/-
Date: 04.08.2025 Arvind Kumar Lohia
Place: Kolkata Managing Director
The Notice is also available on the
Company's website at www.eitain.com and
on the Stock Exchange website at www.cse-
india.com .

**QGO FINANCE LIMITED**
CIN : L65910MH1993PLC302405
Regd Office:3rd Floor, A-514, TTC Industrial Area, MIDC, Mahape, Navi Mumbai – 400701
E:Contactus@qgofinance.com/Website:www.qgofinance.com/Tel No.: +91-8657400776

[Regulation 47 of the SEBI (LODR) Regulations, 2015]
BSE Code - 538646
Extract of Un-Audited Financial Results for the quarter ended June 30, 2025
The Un-Audited Financial Results of QGO Finance Limited ("the Company") along with the Limited Review Report received from the Statutory Auditors of the Company for the Quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by Board of Directors of the Company at their Meetings held on August 04, 2025, in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The aforementioned Financial Results along with the Limited Review Report of the Statutory Auditors thereon are available on the website of BSE (www.bseindia.com) and on the Company's website at <https://qgofinance.com/>. The same can also be accessed by scanning the QR Code provided below:
**By order of the Board
For QGO Finance Limited**
Sd/-
Rachana Singi
Managing Director

Date: 04/08/2025
Place: Navi Mumbai

**MERCANTILE VENTURES LIMITED**
CIN: L65191TN1985PLC037309
Regd. Office: 88, Mount Road, Guindy, Chennai - 600 032 Tel: 044-40432209
Email: admin@mercantileventures.co.in website: www.mercantileventures.co.in

**UNAUDITED FINANCIAL RESULTS FOR THE
QUARTER ENDED 30TH JUNE 2025**
In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Board of Directors of Mercantile Ventures Limited ("Company") at its meeting held on Monday, 04th August 2025 approved the Unaudited Standalone and Consolidated financial results for the quarter ended 30th June 2025 ("results").

The results, along with the limited review report (standalone and consolidated) by M/s. Venkatesh & Co, Statutory Auditor of the Company are available on the website of the Company at <https://www.mercantileventures.co.in/>, and on website of the Stock Exchange i.e. BSE Limited at www.bseindia.com.

In compliance with Regulation 47 of the SEBI Listing Regulations, we hereby notify that the same can be accessed by scanning the following Quick Response (QR) code:
**For Mercantile Ventures Limited**
E N Rangaswami
Whole-time Director
DIN: 06463753

Place: Chennai
Date : 04.08.2025

**NEOCHEM**
Enabling Growth
NEOCHEM BIO SOLUTIONS LIMITED
(Formerly known as Neochem Bio Solutions Private Limited and Neochem Technologies Private Limited)
CORPORATE IDENTIFICATION NUMBER: U24304GJ2017PLC097754
Our Company was originally formed as a partnership firm under the Indian Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Vinayak Dyes & Chemical Industries", pursuant to Deed of Partnership dated March 6, 1978. Vinayak Dyes & Chemical Industries was changed to "Neochem Technologies" with effect from January 6, 2006 and further the firm was converted from Partnership Firm to Private Limited company under Part I chapter XXI of the Companies Act, 2013 and received a Certificate of Incorporation from Registrar of Companies, Ahmedabad at Gujarat ("RoC") on June 6, 2017 as "Neochem Technologies Private Limited". Furthermore, the name of our Company was changed from Neochem Technologies Private Limited to Neochem Bio Solutions Private Limited and Certificate of Name change dated March 18, 2025 was received by the Company. Subsequently, our Company was converted into a public limited company pursuant to a special resolution passed by our shareholders resolution dated March 26, 2025, and the name of our Company was changed to "Neochem Bio Solutions Limited". A fresh certificate of Incorporation consequent upon conversion from a Private Limited company to Public Limited company dated April 15, 2025 was issued by the Registrar of Companies, Central Processing Centre. For details of the change in the registered office of our Company, see "History and Certain Corporate Matters" on page 200 of the Draft Red Herring Prospectus.
Registered Office: 303, W1, Opp. Vikramnagar Colony, Off. Iscon - Ambli Road, Ambli, Ahmedabad - 380058, Daskroi, Gujarat, India.
Website: www.neochem.in; **E-Mail:** compliance@neochem.in; **Telephone No:** +91 -079- 35217792
Company Secretary and Compliance Officer: Shradha Sarthak Agarwal; **Chief Financial Officer:** Pradipt Ramniklal Sanki

PROMOTERS OF OUR COMPANY: SWAPNIL RAMESHBHAI MAKATI AND HEMANGINI SWAPNIL DATHIA
THE ISSUE
INITIAL PUBLIC ISSUE OF UPTO 47,50,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH OF NEOCHEM BIO SOLUTIONS LIMITED (FORMERLY KNOWN AS NEOCHEM BIO SOLUTIONS PRIVATE LIMITED & NEOCHEM TECHNOLOGIES PRIVATE LIMITED), ("NEOCHEM" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹[•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹[•]/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹[•] LAKHS ("THE ISSUE"), OF WHICH [•] EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹[•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹[•]/- PER EQUITY SHARE AGGREGATING TO ₹[•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF [•] EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹[•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹[•]/- PER EQUITY SHARE AGGREGATING TO ₹[•] LAKHS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE [•] AND [•], RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.
THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER ADVERTISED IN ALL EDITION OF [•] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND ALL EDITION OF [•] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND GUJARATI EDITION OF [•] (A WIDELY CIRCULATED GUJARATI DAILY NEWSPAPER, GUJARATI BEING THE REGIONAL LANGUAGE OF GUJARAT, WHERE OUR REGISTERED OFFICE IS LOCATED). AT LEAST TWO WORKING DAYS PRIOR TO THE ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE") FOR THE PURPOSE OF UPLOADING ON THEIR WEBSITE. FOR FURTHER DETAILS, KINDLY REFER TO CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 305 OF THE DRAFT RED HERRING PROSPECTUS.
In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least 3 (three) additional Working Days after such revision of the Price Band, subject to the total Bid/ Issue Period not exceeding 10 (ten) Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, in consultation with the BRLM, for reasons to be recorded in writing, extend the Bid/ Issue Period for a minimum of 1 (one) Working Day, subject to the Bid/Issue Period not exceeding 10 (ten) Working Days. Any revision in the Price Band, and the revised Bid/ Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchange, by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.
THE FACE VALUE OF THE EQUITY SHARES IS ₹10/- EACH AND THE ISSUE PRICE IS [•] TIMES OF THE FACE VALUE
This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders wherein (a) one third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs; (b) two third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than ₹10 lakhs; and (c) any unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), may be allocated to Applicants in the other sub-category of Non-Institutional Investors; and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCRBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" on page 320 of the Draft Red Herring Prospectus.
This Public Announcement is made pursuant to Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Amendment) Regulations, 2025 vide notification dated March 03, 2025.
The DRHP filed with the NSE EMERGE shall be made available for the public comments, if any, for the period of at least 21 days from the date of such filing and hosting the same on the website of the NSE at www.nseindia.com, website of the Issuer at www.neochem.in and on the website of BRLM i.e. Vivro Financial Services Private Limited at www.vivro.net. Our Company invites the public to give their comments on the DRHP filed with the NSE, with respect to the disclosures made in the DRHP. The members of the public are requested to send the copies of their comments to NSE EMERGE and/or Company Secretary and the Compliance Officer of the Issuer and/or BRLM at their respective address mentioned below and the same should reach on or before 5:00 P.M. on the 21st day from the aforesaid date of filing of DRHP with NSE EMERGE.
Investment in equity and equity related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. In taking an investment decision, investors must rely on their own examination of the issuer and the Issue including the risks involved. The securities have not been recommended or approved by the Securities and Exchange Board of India ("SEBI") nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of investors is invited to the section titled "Risk factors" on page 31 of the Draft Red Herring Prospectus.
Any investment decision may only be taken after the red herring prospectus ("Red Herring Prospectus" or "RHP") has been filed with RoC and must be based solely on the basis of such RHP, as there may be any material changes in the RHP from the DRHP. Equity Shares, when offered through RHP are proposed to be listed on NSE EMERGE.
For details of share capital and capital structure of the Company and the names of the signatories to the Memorandum of the Association and number of Equity Shares subscribed by them, see "Capital Structure" on page 87 of the DRHP. The Liability of the members of our company is limited.
For details of the main objects of the issuer as contained in the Memorandum of the Association, see "History and Certain Corporate Matters" on page 200 of the DRHP.

BOOK RUNNING LEAD MANAGER TO THE ISSUE
VIVRO
Vivro Financial Services Private Limited
Vivro House, 11 Shashi Colony,
Opp Suvidha Shopping Center,
Paladi, Ahmedabad – 380007
Gujarat, India.
Telephone: +91-79-4040 4242
E-mail Id: investors@vivro.net
Investor Grievance Id:
investors@vivro.net
Website: www.vivro.net
Contact Person: Kruti Saraiya/Jay Dodiya
SEBI Registration No.: INM000010122
CIN: U67120GJ1996PTC029182

REGISTRAR TO THE ISSUE
MUFG
MUFG Intime India Private Limited
(Formerly known as
Link Intime India Private Limited)
C-101, 247 Park, L B S Marg, Vikhroli (West),
Mumbai 400083, (Maharashtra), India.
Telephone: +91 810 811 4949
Website: www.in.mpgs.mufg.com
Email ID: neochem.smeipo@in.mpgs.mufg.com
Investor Grievance:
neochem.smeipo@in.mpgs.mufg.com
Contact Person: Shanti Gopalkrishnan
SEBI Registration No.: INR000004058
CIN: U67190MH1999PTC118368

COMPANY SECRETARY AND COMPLIANCE OFFICER
NEOCHEM
Enabling Growth
Neochem Bio Solutions Limited
Shradha Sarthak Agarwal
Company Secretary and Compliance Officer
303, W1, Opp. Vikramnagar Colony, Off. Iscon - Ambli Road,
Ambli, Ahmedabad - 380058, Daskroi, Gujarat, India.
Telephone: +91 -079- 35217792
Email Id: compliance@neochem.in
Website: www.neochem.in
Investors can contact the Company Secretary and Compliance Officer, the BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related grievances, such as non-receipt of Letters of Allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode.

All the capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in DRHP.
For, Neochem Bio Solutions Limited
Sd/-
Shradha Sarthak Agarwal
Company Secretary & Compliance Officer
Date : August 4, 2025
Place : Ahmedabad
Neochem Bio Solutions Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and considerations, to make initial public issue of Equity Shares and has filed DRHP with NSE EMERGE on August 4, 2025. The DRHP is available on the website of NSE at www.nseindia.com, Issuer at www.neochem.in and on the website of BRLM i.e. Vivro Financial Services Private Limited at www.vivro.net. Any potential investor should note that the investment in the Equity Shares involves high degree of risk and for details relating to such risk kindly refer "Risk Factors" on page 31 of the DRHP. Potential investors should not rely on the DRHP filed with NSE EMERGE for making any investment decision.
The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur.
There will be no public offering of the Equity Shares in the United States.
KIRIN ADVISORS

PATEL KNR HEAVY INFRASTRUCTURES LIMITED
CIN: U70102TG2006PLC049949
Regd Office: KNR House, 4th Floor, Plot No.114, Phase-1, Kavuri Hills,
Hyderabad-500033. Ph: +91 40 40268761/62, Fax: +91 40 40268760

**EXTRACT OF AUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH JUNE, 2025** (RS IN LAKHS)

Sl. No.	PARTICULARS	Standalone			
		Quarter Ended 30-06-2025 Unaudited	Quarter Ended 30-06-2024 Unaudited	Quarter Ended 31-03-2025 Unaudited	Year Ended 31-03-2025 Unaudited
1.	Total income from operations	835.06	991.05	837.77	31,123.61
2.	Net Profit / (Loss) for the period (before Tax, Exceptional items)	192.51	83.29	- 400.32	- 1,047.85
3.	Net Profit / (Loss) for the period (before Tax, After Exceptional items)	192.51	83.29	- 400.32	- 1,047.85
4.	Net Profit / (Loss) for the period (after Tax, Exceptional items)	177.55	- 109.92	- 472.88	- 1,802.42
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	177.55	- 109.92	- 472.88	- 1,802.42
6.	Paid up Equity Share Capital	2,382.38	2,382.38	2,382.38	2,382.38
7.	Debt Equity Ratio	0.53	1.55	0.55	0.55
8.	Earnings Per Share				
	1. Basic: (Rs.)	0.75*	-0.46*	-1.98*	(7.57)
	2. Diluted: (Rs.)	0.75*	-0.46*	-1.98*	(7.57)
9.	Debt Redemption Reserve	521.20	2,442.00	527.20	527.20
10.	Debt Service Coverage Ratio #	2.96	1.14	0.00	0.07
11.	Interest Service Coverage Ratio #	1.90	1.17	(0.54)	0.45

* Not Annualized
The Debt Service Coverage ratio and Interest Service Coverage ratio is below one due to IND-AS impacts and early redemption of Debentures.
Notes:
1. The above is an extract of the detailed format of Financial Results for the Quarter ended June,2025 filed with the Stock Exchange under Regulation 52 of Listing Regulations. The full format of the quarter ended June 2025 Financial Results are available on the Stock Exchange website namely, BSE Limited (www.bseindia.com).
2. The above financial results were reviewed and approved and taken on record by the Board in their meeting held on 01st August, 2025
3. The figures have been regrouped and/or rearranged wherever considered necessary.

For Patel KNR Heavy Infrastructures Ltd
Sd/-
(Rahul Agarwal)
Director
DIN: 08407819
Place : Hyderabad
Date : 04-08-2025

**MUTUALFUNDS**
Sahi hai
**uti**
UTI Mutual Fund
Haq, ek behtar zindagi ka.

**Notice For Declaration Of
Income Distribution Cum Capital Withdrawal**
UTI Aggressive Hybrid Fund (Erstwhile UTI Hybrid Equity Fund)

Name of the Plan	Quantum of IDCW (Gross Distributable Amt.)*		Record Date	Face Value (per unit)	NAV as on August 01, 2025 (per unit)
	%	₹ per unit			
UTI Aggressive Hybrid Fund Regular Plan - Payout of Income Distribution cum Capital Withdrawal option (IDCW)	9.00%	0.9000	Thursday August 07, 2025	₹10.00	42.6281
UTI Aggressive Hybrid Fund Direct Plan - Payout of Income Distribution cum Capital Withdrawal option (IDCW)					47.6573

*Distribution of above IDCW is subject to the availability of distributable surplus as on record date. Income distribution cum capital withdrawal payment to the investor will be lower to the extent of statutory levy (if applicable). Income distribution will be made, net of tax deducted at source as applicable.
Pursuant to payment of IDCW, the NAV of the income distribution cum capital withdrawal options of the scheme would fall to the extent of payout and statutory levy (if applicable).
Such of the unitholders under the income distribution cum capital withdrawal options whose names appear in the register of unitholders as at the close of business hours on the record date fixed for each income distribution cum capital withdrawal shall be entitled to receive the income distribution cum capital withdrawal so distributed. The reinvestment, if any, shall be treated as constructive payment of IDCW to the unitholders as also constructive receipt of payment of the amount by the unitholders. No load will be charged on units allotted on reinvestment of IDCW.

Mumbai
August 04, 2025
Toll Free No.: 1800 266 1230
www.utmif.com
REGISTERED OFFICE: UTI Tower, "Gn" Block, Bandra Kurla Complex, Bandra (E), Mumbai - 400051. Phone: 022 - 66786666. UTI Asset Management Company Ltd. (Investment Manager for UTI Mutual Fund) E-mail: invest@uti.co.in, (CIN-L65991MH2002PLC137867).
For more information, please contact the nearest UTI Financial Centre or your AMFI/ NISM certified Mutual Fund Distributor, for a copy of Statement of Additional Information, Scheme Information Document and Key Information Memorandum cum Application Form.
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

THE BUSINESS DAILY FOR DAILY BUSINESS

FINANCIAL EXPRESS

Read to Lead

epaper.financialexpress.com